[Evaluation of the kinetics of MB creatine kinase in patients undergoing systemic thrombolytic therapy].
This study was aimed to evaluate if the time-course of creatinkinase MB in acute myocardial infarction (AMI) is influenced by therapy and which index, derived from the enzymatic curve, is the most reliable marker of successful coronary artery recanalization. We studied the enzymatic curves in 38 patients with transmural myocardial infarction, 19 treated with streptokinase (SK) and 19 with tissue plasminogen activator (rtPA). Blood samples were obtained every 2 hours for the first 12 hours and every 6 hours until the level of serum CK returned to baseline. Three indexes were calculated: peak serum enzyme level, time to peak enzyme level and maximal enzyme rise velocity. Time to peak did not differ significantly between SK and rtPA groups. Peak levels were significantly higher (414 +/- 40 vs 249 +/- 33; p = 0.004) in rtPA groups, as well as maximal enzyme rise velocity (1.7 +/- 0.4 vs 0.8 +/- 0.1; p = 0.02). However, infarct size evaluated by the total release of CK-MB in 28 patients was greater in rtPA group (10949 +/- 1097 vs 6346 +/- 869; p = 0.002). These findings suggest that differences in peak level and in maximal velocity of rise observed between SK and rtPA are due to differences in infarct size and not to a different recanalization rate. Thus, enzymatic estimate of infarct size significantly correlates to peak enzyme (r = 0.894, p less than 0.001), and to maximal rise velocity (r = 0.518, p = 0.007) but not to time to peak (r = 0.208, NS).(ABSTRACT TRUNCATED AT 250 WORDS)
Arrigo
F
F
Istituto Pluridisciplinare di Clinica e Terapia Medica I, Università degli Studi, Messina.
Saccà
C M
CM
Cavalli
A
A
Egitto
M
M
Barillari
M
M
Costa
G
G
Cavalli
G
G
Carerj
S
S
Melluso
C
C
D003402:Creatine Kinase / Q000097:blood* / Q000187:drug effects; D005260:Female; D006801:Humans; D007527:Isoenzymes; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D013300:Streptokinase / Q000494:pharmacology / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use*
D007527:Isoenzymes; D003402:Creatine Kinase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator
Valutazione della cinetica della CK-MB in pazienti sottoposti a terapia trombolitica sistemica.